Cargando…

Systemic chemotherapy for gastro-oesophagogastric junction adenocarcinoma and stomach adenocarcinoma in a metastatic setting

Detalles Bibliográficos
Autores principales:	Sanjeevaiah, Aravind, McGehee, Elizabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351278/ https://www.ncbi.nlm.nih.gov/pubmed/32646964 http://dx.doi.org/10.1136/esmoopen-2020-000802

Ejemplares similares

Single-institute comparison of the efficacy of systemic chemotherapy for oesophagogastric junction adenocarcinoma and stomach adenocarscinoma in a metastatic setting
por: Nakayama, Izuma, et al.
Publicado: (2020)

Comment on: Impact of postoperative chemotherapy on survival for oesophagogastric adenocarcinoma after preoperative chemotherapy and surgery
por: Liu, Kai, et al.
Publicado: (2022)

Author response to: Impact of postoperative chemotherapy on survival for oesophagogastric adenocarcinoma after preoperative chemotherapy and surgery
por: Rahman, Saqib A, et al.
Publicado: (2022)

Spontaneous Regression of Metastatic Lesions of Adenocarcinoma of the Gastro-Esophageal Junction
por: Mitchell, Richard, et al.
Publicado: (2021)

Treatment for metastatic adenocarcinoma of the stomach and gastroesophageal junction: 2020
por: Hsu, Andrew, et al.
Publicado: (2020)

Enduring complete metabolic response in metastatic adenocarcinoma of the gastro-oesophageal junction
por: Li, Minmin, et al.
Publicado: (2014)

Dose-escalated neoadjuvant chemoradiotherapy for locally advanced oesophageal or oesophagogastric junctional adenocarcinoma
por: Duque-Santana, Victor, et al.
Publicado: (2022)

Impact of postoperative chemotherapy on survival for oesophagogastric adenocarcinoma after preoperative chemotherapy and surgery
por: Rahman, Saqib, et al.
Publicado: (2021)

Clinical importance of serum CEA and CA-19-9 levels in oesophagogastric junction adenocarcinomas
por: Sert, Ozlem Zeliha, et al.
Publicado: (2020)

Association of metabolism‐related genes polymorphisms with adenocarcinoma of the oesophagogastric junction: Evidence from 2261 subjects
por: Tang, Weifeng, et al.
Publicado: (2019)

EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus
por: Birkman, Eva-Maria, et al.
Publicado: (2016)

Perioperative Therapy of Oesophagogastric Adenocarcinoma: Mainstay and Future Directions
por: Bose, Katrin, et al.
Publicado: (2017)

Total neoadjuvant chemotherapy with FLOT scheme in resectable adenocarcinoma of the gastro-oesophageal junction or gastric adenocarcinoma: impact on pathological complete response and safety
por: Villanueva, Luis, et al.
Publicado: (2021)

Impact of the Siewert Classification on the Outcome of Patients Treated by Preoperative Chemoradiotherapy for a Nonmetastatic Adenocarcinoma of the Oesophagogastric Junction
por: Moureau-Zabotto, Laurence, et al.
Publicado: (2015)

Establishment of prognostic models for adenocarcinoma of oesophagogastric junction patients with neoadjuvant chemoradiotherapy: a real-world study
por: Du, Rongxu, et al.
Publicado: (2022)

Prognostic Value of the Systemic Inflammation Response Index in Patients with Adenocarcinoma of the Oesophagogastric Junction: A Propensity Score-Matched Analysis
por: Chen, Yuan, et al.
Publicado: (2019)

Opposing Immune-Metabolic Signature in Visceral Versus Subcutaneous Adipose Tissue in Patients with Adenocarcinoma of the Oesophagus and the Oesophagogastric Junction
por: Heeran, Aisling B., et al.
Publicado: (2021)

Successes and failures of angiogenesis blockade in gastric and gastro-esophageal junction adenocarcinoma
por: Salati, Massimiliano, et al.
Publicado: (2022)

ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS)
por: Reynolds, JV, et al.
Publicado: (2017)

Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma
por: Davidson, Michael, et al.
Publicado: (2016)

Economic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma
por: Zeng, Hanqing, et al.
Publicado: (2022)

Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium
por: Hoyo, Cathrine, et al.
Publicado: (2012)

PD-1 blockade attenuates surgery-mediated immunosuppression and boosts Th1 immunity perioperatively in oesophagogastric junctional adenocarcinoma
por: Davern, Maria, et al.
Publicado: (2023)

Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial
por: Reynolds, John V, et al.
Publicado: (2023)

Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas
por: Schmidt, T, et al.
Publicado: (2014)

The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction
por: Curtis, Nathan J, et al.
Publicado: (2014)

The Evolution of Neo-Adjuvant Therapy in the Treatment of Oesophageal and Gastro-Oesophageal Junction Adenocarcinomas
por: Dermanis, Alexander A., et al.
Publicado: (2023)

Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric Adenocarcinoma
por: Davidson, Michael, et al.
Publicado: (2019)

Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction
por: Wainberg, Z A, et al.
Publicado: (2011)

A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma
por: Starling, N, et al.
Publicado: (2009)

Semi-embedded valve anastomosis a new anti-reflux anastomotic method after proximal gastrectomy for adenocarcinoma of the oesophagogastric junction
por: Wang, Baohua, et al.
Publicado: (2020)

Postoperative Chemoradiotherapy Combined with Epirubicin-Based Triplet Chemotherapy for Locally Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction
por: Li, Guichao, et al.
Publicado: (2013)

Quality assurance of surgery in the randomized ST03 trial of perioperative chemotherapy in carcinoma of the stomach and gastro‐oesophageal junction
por: Allum, W. H., et al.
Publicado: (2019)

Significance of tumour regression in lymph node metastases of gastric and gastro‐oesophageal junction adenocarcinomas
por: Reim, Daniel, et al.
Publicado: (2020)

Minimally invasive surgery for gastro-oesophageal junction adenocarcinoma: Current evidence and future perspectives
por: Bîrlă, Rodica, et al.
Publicado: (2023)

A Pilot Study to Investigate the Role of Thymidylate Synthase as a Marker of Prognosis for Neoadjuvant Chemotherapy in Gastric and Gastro-Oesophageal Junction Adenocarcinoma
por: Mirza, A., et al.
Publicado: (2013)

A novel risk score system for prognostic evaluation in adenocarcinoma of the oesophagogastric junction: a large population study from the SEER database and our center
por: Wang, Jun, et al.
Publicado: (2021)

Cutaneous metastatic adenocarcinoma of stomach--nodular and inflammatory carcinoma.
por: Choi, H. M., et al.
Publicado: (1986)

Gastrointestinal Bleeding from Metastatic Prostate Adenocarcinoma to the Stomach
por: Koop, Andree, et al.
Publicado: (2017)

Effectiveness and Safety of Apatinib in Patients with Advanced or Metastatic Adenocarcinoma of Stomach or Gastroesophageal Junction: A Prospective Observation Study
por: Shen, Bo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q8ge2un5sgictt9mhgn7dlli82